Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Margin
Hansoh Pharmaceutical Group Company Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
139.8B HKD |
41%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
838.8B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
375.1B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
215.6B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189.4B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
166.9B GBP |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
214.1B USD |
35%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
134.8B USD |
25%
|
Hansoh Pharmaceutical Group Company Ltd
Glance View
Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Hansoh Pharmaceutical Group Company Ltd's most recent financial statements, the company has Operating Margin of 41.2%.
You don't have any saved screeners yet